Henrik Zetterberg

Summary

Country: Sweden

Publications

  1. ncbi Cerebrospinal fluid markers for prediction of Alzheimer's disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Gothenburg, Sweden
    Neurosci Lett 352:67-9. 2003
  2. ncbi Characterization of tau in cerebrospinal fluid using mass spectrometry
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, S 431 80 Molndal, Sweden
    J Proteome Res 7:2114-20. 2008
  3. ncbi Longitudinal stability of CSF biomarkers in Alzheimer's disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden
    Neurosci Lett 419:18-22. 2007
  4. ncbi Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:401-7. 2012
  5. ncbi Identification of novel APP/Abeta isoforms in human cerebrospinal fluid
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
    Neurodegener Dis 6:87-94. 2009
  6. ncbi Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
    Magnus Gisslen
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, SE 416 85 Gothenburg, Sweden
    BMC Neurol 9:63. 2009
  7. ncbi Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract
    Malin von Otter
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Bla Straket 15, the Sahlgrenska Academy at University of Gothenburg, S 413 45 Gothenburg, Sweden
    Mech Ageing Dev 131:105-10. 2010
  8. ncbi Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:409-17. 2012
  9. ncbi Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, S 431 80 Molndal, Sweden
    J Proteome Res 6:4433-9. 2007
  10. ncbi Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method
    Annika Ohrfelt
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, S 43180 Mölndal, Sweden
    Neurochem Res 36:2029-42. 2011

Detail Information

Publications69

  1. ncbi Cerebrospinal fluid markers for prediction of Alzheimer's disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Gothenburg, Sweden
    Neurosci Lett 352:67-9. 2003
    ..The usefulness of these markers is further emphasized by the finding of a positive predictive value of 94% and a negative predictive value of 81%...
  2. ncbi Characterization of tau in cerebrospinal fluid using mass spectrometry
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, S 431 80 Molndal, Sweden
    J Proteome Res 7:2114-20. 2008
    ..Nineteen tryptic fragments of tau were detected, of which 16 are found in all tau isoforms while 3 represented unique tau isoforms. These results pave the way for clinical CSF studies on the tauopathies...
  3. ncbi Longitudinal stability of CSF biomarkers in Alzheimer's disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden
    Neurosci Lett 419:18-22. 2007
    ....
  4. ncbi Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:401-7. 2012
    ..Global proficiency testing for CSF biomarkers is now fully established. It will continue to play an important part in the standardization of measurements that is a prerequisite for the broad-scale future implementation of CSF biomarkers...
  5. ncbi Identification of novel APP/Abeta isoforms in human cerebrospinal fluid
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
    Neurodegener Dis 6:87-94. 2009
    ..A lot of research has focused on Abeta production and the neurotoxic 42-amino-acid form of Abeta (Abeta1-42), while less is known about the nonamyloidogenic pathway and how Abeta is degraded...
  6. ncbi Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
    Magnus Gisslen
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, SE 416 85 Gothenburg, Sweden
    BMC Neurol 9:63. 2009
    ..Because of the emerging intersections of HIV infection and Alzheimer's disease, we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism in HIV-infected patients...
  7. ncbi Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract
    Malin von Otter
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Bla Straket 15, the Sahlgrenska Academy at University of Gothenburg, S 413 45 Gothenburg, Sweden
    Mech Ageing Dev 131:105-10. 2010
    ..009). Our findings do not support NFE2L2 or KEAP1 as susceptibility genes for AD or cataract. However, common variants of the NFE2L2 gene may affect disease progression, potentially altering clinically recognized disease onset...
  8. ncbi Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Biomark Med 6:409-17. 2012
    ..We describe possible technical approaches, focusing on a selected reaction monitoring mass spectrometry assay as a candidate reference method for quantification of CSF amyloid β42...
  9. ncbi Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, S 431 80 Molndal, Sweden
    J Proteome Res 6:4433-9. 2007
    ..Finally, we report the finding of two novel Abeta peptides (Abeta2-17 and Abeta3-17)...
  10. ncbi Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method
    Annika Ohrfelt
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, S 43180 Mölndal, Sweden
    Neurochem Res 36:2029-42. 2011
    ..Quantification of α-syn in each brain tissue fraction was performed using a novel enzyme-linked immunosorbent assay (ELISA)...
  11. ncbi An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
    Neurosci Lett 409:215-9. 2006
    ..Here, we provide direct evidence that an Abeta fragment signature consisting of Abeta1-16, Abeta1-33, Abeta1-39, and Abeta1-42 in CSF distinguishes sporadic AD patients from non-demented controls with an overall accuracy of 86%...
  12. ncbi Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid
    Adnan Halim
    Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, SE 413 45 Gothenburg, Sweden
    Proc Natl Acad Sci U S A 108:11848-53. 2011
    ..APP/Aβ sialylated O-glycans, including that of a Tyr residue, the first in a mammalian protein, may modulate APP processing, inhibiting the amyloidogenic pathway associated with AD...
  13. ncbi Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Gothenburg, Sweden
    Neurosci Lett 367:194-6. 2004
    ..35; P = 0.020), although this correlation failed to reach significance in the AD group alone (r = -0.38; P = 0.099). Taken together, the data indicate that TGF-beta1 plays a role in the processes that affect amyloid metabolism in AD...
  14. ncbi Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease
    Annica Johansson
    Department of Clinical Neuroscience, Sahlgrenska University Hospital, Goteborg University, Goteborg, Sweden
    Hum Genet 114:581-7. 2004
    ..Our results provide an important independent replication of previous findings, supporting the existence of CYP46A1 sequence variants that contribute to variability in beta-amyloid metabolism...
  15. ncbi Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF
    Ulla Ruetschi
    Institute of Laboratory Medicine, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, Sweden
    Exp Neurol 196:273-81. 2005
    ..With use of these potential biomarkers, FTD can be distinguished from control subjects with high accuracy in this pilot study...
  16. ncbi Methylenetetrahydrofolate reductase genetic polymorphisms in patients with cataract
    Madeleine Zetterberg
    Institute of Clinical Neuroscience, Section of Ophthalmology, Sahlgrenska University Hospital, Goteborg University, Molndal, Sweden
    Am J Ophthalmol 140:932-4. 2005
    ..The level of homocysteine can be lowered by dietary intake of folate. A protective effect of folate supplementation has been reported against cataract. Here we investigate MTHFR polymorphisms in human cataract...
  17. ncbi The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis
    Camilla Hesse
    Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine, The Sahlgrenska Academy, University of Gothenburg, Sweden
    Biochem Biophys Res Commun 412:494-9. 2011
    ..In untreated acute phase LNB patients, 67% showed a significant increase of CSF α-DG-N compared to healthy controls. After treatment with antibiotics the CSF α-DG-N levels were normalized in the LNB patients...
  18. ncbi The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
    Niklas Mattsson
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
    Alzheimers Dement 7:386-395.e6. 2011
    ..In this article, we present the results from the first two rounds of the program...
  19. ncbi Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Goteborg, Sweden
    Hum Reprod 18:1948-50. 2003
    ..It was hypothesized that there may be a significant interaction between MTHFR and TC genotypes which affects the pathogenesis of spontaneous abortion...
  20. ncbi CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma
    Sanna Neselius
    Department of Orthopaedics, Sahlgrenska University Hospital, Gothenburg, Sweden
    PLoS ONE 7:e33606. 2012
    ..Further the effects of recurrent head trauma on brain injury markers are unknown. The purpose of this study was to investigate the relationship between Olympic (amateur) boxing and cerebrospinal fluid (CSF) brain injury biomarkers...
  21. ncbi Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease
    Kaj Blennow
    Institute of Clinical Neuroscience, Department of Experimental Neuroscience, Sahlgrenska University Hospital, , , Sweden
    Int J Mol Med 16:1147-9. 2005
    ..023). The high predictive values achieved by the combined tau test suggest that it could be used in conjunction with other diagnostic methods for accurate intra vitam diagnosis of CJD...
  22. ncbi Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk
    Annica Sjölander
    Department of Clinical Chemistry and Transfusion Medicine, Molecular Biology, The Sahlgrenska Academy at Goteborg University, Sahlgrenska University Hospital, SE 413 45 Goteborg, Sweden
    Mol Med Report 2:989-92. 2009
    ..We found no significant differences in genotype or allele distributions between AD patients and controls. None of the CDK5 gene variants influenced biomarkers for AD...
  23. ncbi Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis
    Henrik Zetterberg
    Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital, Goteborg University, Sweden
    J Neurol Sci 273:67-9. 2008
    ..027). These data support APOE epsilon4 as a subordinate contributing factor in ALS...
  24. ncbi B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia
    Daniel Kondziella
    Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
    Neuroreport 20:825-7. 2009
    ..This probably reflects the larger cardiovascular burden in patients with subcortical vascular dementia...
  25. ncbi Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery
    Björn Reinsfelt
    Department of Cardiothoracic Anesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden
    Ann Thorac Surg 94:549-55. 2012
    ....
  26. ncbi Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation
    Ulla Ruetschi
    Department of Clinical Chemistry and Transfusion Medicine, Perinatal Center, Department of Obstetrics and Gynecology, Institute for the Health of Women and Children, Sahlgrenska University Hospital, Goteborg, Sweden
    J Proteome Res 4:2236-42. 2005
    ..Five of these were identified as human neutrophil protein 1-3, calgranulin A and B...
  27. ncbi BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
    Annica Sjölander
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital, University of Gothenburg, Sweden
    Mol Neurodegener 5:37. 2010
    ..e., total-tau and phospho-tau181. Gene variants of BACE1 were neither associated with amyloid-related biomarkers, nor with markers for axonal degeneration in AD...
  28. ncbi Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders
    Radu Constantinescu
    Department of Neurology, Sahlgrenska University Hospital, 413 45 Goteborg, Sweden
    Parkinsonism Relat Disord 16:142-5. 2010
    ..Our results suggest that measurements of CSF NFL but not GFAP can be useful in the differential diagnosis of PD versus atypical parkinsonian disorders (APD). However they do not help differentiate between the different APD...
  29. ncbi Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Goteborg, Sweden
    Reprod Biol Endocrinol 2:7. 2004
    ....
  30. ncbi Multiple EBNA1-binding sites within oriPI are required for EBNA1-dependent transactivation of the Epstein-Barr virus C promoter
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Goteborg, Sweden
    Int J Oncol 25:693-6. 2004
    ....
  31. ncbi Hyperphosphorylation of tau protein in superficial CNS siderosis
    Daniel Kondziella
    Department of Neurology, Sahlgrenska University Hospital, Goteborg, Sweden
    J Neurol Sci 273:130-2. 2008
    ..The results indicate that in superficial CNS siderosis neurodegeneration may be secondary to iron toxicity and oxidative stress. Similar mechanisms have been suggested for other neurodegenerative disorders such as Alzheimer's disease...
  32. ncbi Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry
    Erik Portelius
    Institute of Clinical Neuroscience, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43180 Mölndal, Sweden
    J Proteome Res 5:1010-6. 2006
    ..Finally, the Abeta fragment signatures may prove useful as a diagnostic test for AD...
  33. ncbi Association of pro-ghrelin and GHS-R1A gene polymorphisms and haplotypes with heavy alcohol use and body mass
    Sara Landgren
    Institute of Neuroscience and Physiology, Department of Pharmacology, Goteborg University, Goteborg, Sweden
    Alcohol Clin Exp Res 32:2054-61. 2008
    ..This overlap prompted as to investigate the pro-ghrelin and GHS-R1A genes in a haplotype analysis of heavy alcohol-using individuals...
  34. ncbi Fluid biomarkers in Alzheimer disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, SE 431 80 Molndal, Sweden
    Cold Spring Harb Perspect Med 2:a006221. 2012
    ..The rationale for the use of CSF biomarkers to identify and monitor the mechanism of action of new drug candidates is also outlined in this chapter...
  35. ncbi Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, SE 431 80 Molndal, Sweden
    Alzheimers Res Ther 2:8. 2010
    ..More details are needed, however, on how these biomarkers can be standardized, to allow a general implementation in the clinical routine diagnostic work-up of patients with cognitive disturbances...
  36. ncbi The szilard hypothesis on the nature of aging revisited
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, University of Gothenburg, S 413 45 Gothenburg, Sweden
    Genetics 182:3-9. 2009
    ..Here, we review Szilard's assumptions in the light of current knowledge on aging and reassess his mathematical model in an attempt to reach a conclusion on the relevance of Szilard's aging hypothesis today...
  37. ncbi The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, , S-413 45 Gothenburg, Sweden
    Clin Chem 49:1195-8. 2003
  38. ncbi Evaluation of factors of importance for clinical dementia diagnosis
    Katarina Nagga
    Department of Geriatric Medicine, Linkoping University Hospital, Linkoping, Sweden
    Dement Geriatr Cogn Disord 19:289-98. 2005
    ..The different diagnoses overlapped. There were indications that genotypes of GSTs contributed to a subgrouping within AD...
  39. ncbi Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women
    Deborah R Gustafson
    The Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Neuropsychiatric Epidemiology Unit, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Neurol Neurosurg Psychiatry 78:461-4. 2007
    ..It is not known, however, whether these biomarkers may be risk indicators for cognitive decline in otherwise healthy older people...
  40. ncbi Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
    Lars Lannfelt
    Department of Public Health and Geriatrics, Uppsala University Hospital, Uppsala, Sweden
    Lancet Neurol 7:779-86. 2008
    ..Strong preclinical efficacy data and the completion of early, clinical safety studies have preceded this phase IIa study, the aim of which was to assess the effects of PBT2 on safety, efficacy, and biomarkers of AD...
  41. ncbi Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment
    Oskar Hansson
    Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 23:316-20. 2007
    ..05). In conclusion, the data provide further support for the view that amyloid precursor protein metabolism is disturbed in early sporadic AD and points to the usefulness of the Abeta42/Abeta40 ratio as a predictive biomarker for AD...
  42. ncbi Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
    Oskar Hansson
    Clinical Memory Research Unit, Department of Clinical Sciences Malm, Lund University, Sweden
    Lancet Neurol 5:228-34. 2006
    ..8). INTERPRETATION: Concentrations of T-tau, P-tau181, and Abeta42 in CSF are strongly associated with future development of Alzheimer's disease in patients with MCI...
  43. ncbi Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, The Sahlgrenska Academy at Gothenburg University, Sahlgrenska University Hospital Molndal, S 431 80 Molndal, Sweden
    Recent Pat CNS Drug Discov 3:109-11. 2008
    ..This review provides an update on the current status of research on plasma Abeta as a biomarker for AD in the context of recent patents in the field...
  44. ncbi Targeted proteomics in Alzheimer's disease: focus on amyloid-beta
    Erik Portelius
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Expert Rev Proteomics 5:225-37. 2008
    ..From a longer perspective, establishment of the most effective combinations of different biomarkers and other diagnostic modalities may be foreseen...
  45. ncbi Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease
    Annica Johansson
    Department of Clinical Neuroscience, Unit of Neurochemistry, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Dement Geriatr Cogn Disord 20:367-74. 2005
    ..006, OR = 1.57, 95% CI 1.13-2.17). Our results provide further evidence for an involvement of cdc2 in the pathogenesis of AD...
  46. ncbi Amyloid-related biomarkers for Alzheimer's disease
    Niels Andreasen
    Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Sweden
    Curr Med Chem 15:766-71. 2008
    ....
  47. ncbi TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease
    Annica Johansson
    Department of Clinical Neuroscience, Unit of Neurochemistry, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Neurodegener Dis 2:28-35. 2005
    ..A single nucleotide polymorphism in the STH gene has been suggested to be involved in sporadic AD and is in complete linkage disequilibrium with the TAU haplotype H1...
  48. ncbi Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    J Alzheimers Dis 12:255-60. 2007
    ..Thus, even minor biochemical changes induced by treatment against AD should be detectable using these biomarkers, which bodes well for their usefulness as surrogate markers for drug efficacy in clinical trials...
  49. ncbi The role of biomarkers in clinical trials for Alzheimer disease
    Leon J Thal
    University of California San Diego, Department of Neurosciences, La Jolla, California, USA
    Alzheimer Dis Assoc Disord 20:6-15. 2006
    ..Additionally, biochemical biomarkers in blood or cerebrospinal fluid are assessed. Currently appropriate uses of biomarkers in the study of Alzheimer disease, and areas where additional work is needed, are discussed...
  50. ncbi Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment
    Anja H Simonsen
    Biomarker Discovery Center Facility, Ciphergen Biosystems, Inc, 2100 Copenhagen O, Denmark
    Arch Neurol 64:366-70. 2007
    ..To use proteomic analysis of cerebrospinal fluid to discover novel proteins and peptides able to differentiate between patients with stable mild cognitive impairment (MCI) and those who will progress to Alzheimer disease (AD)...
  51. ncbi Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma
    Madeleine Zetterberg
    Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation, Section of Ophthalmology, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Am J Ophthalmol 143:1059-60. 2007
    ..To investigate apolipoprotein E (APOE) polymorphisms, which are known to influence the risk of Alzheimer disease (AD), in patients with primary open-angle glaucoma (POAG)...
  52. ncbi Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss
    William A Campbell
    Center for Neurologic Diseases, Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA
    J Neurochem 96:1423-40. 2006
    ....
  53. ncbi Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease
    Malin E Andersson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Int J Mol Med 20:233-9. 2007
    ..018). These findings support earlier indications that genetic variability in the KNS2 gene may play a role during early stages of AD pathogenesis...
  54. ncbi [There is a strong evidence that professional boxing results in chronic brain damage. The more head punches during a boxer's career, the bigger is the risk]
    Kaj Blennow
    Institutionen för klinisk neurovetenskap, Sahlgrenska Universitetssjukhuset Mölndal, Sweden
    Lakartidningen 102:2468-70, 2472-5. 2005
    ..Focus is also set on the interesting similarities in neurochemical changes and pathogenic mechanisms between CTBI-B, acute traumatic brain injury (e.g. road traffic accidents) and Alzheimer's disease...
  55. ncbi The transcobalamin 776C > G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease
    Henrik Zetterberg
    Int Psychogeriatr 17:329-31. 2005
  56. ncbi [New investigations in suspected Creutzfeldt-Jakob disease. Analysis of 14-3-3 protein and T-tau in cerebrospinal fluid for safer diagnosis]
    Henrik Zetterberg
    Institutionen för klinisk neurovetenskap, Göteborgs Universitet, Sweden
    Lakartidningen 102:956-8, 960-1. 2005
    ..Here, we review how CSF T-tau and P-tau may aid in the diagnosis of CJD and illustrate this by presenting cases from routine clinical practice...
  57. ncbi Pinpointing plaques with PIB
    Kaj Blennow
    Nat Med 12:753-4; discussion 754. 2006
  58. ncbi Plasma Abeta in Alzheimer's disease--up or down?
    Henrik Zetterberg
    Lancet Neurol 5:638-9. 2006
  59. ncbi Alzheimer's disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, Sahlgren s University Hospital, Molndal, Sweden
    Lancet 368:387-403. 2006
    ..This seminar reviews the key aspects of the disease, including epidemiology, genetics, pathogenesis, diagnosis, and treatment, as well as recent developments and controversies...
  60. ncbi Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis
    Niklas Mattsson
    Department of Neurochemistry and Psychiatry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    J Neurochem 103:1932-9. 2007
    ..Further studies will investigate the involvement of these peptides in MS pathogenesis...
  61. ncbi Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Sweden
    Ann Neurol 63:621-31. 2008
    ....
  62. ncbi Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization
    Igor Klyubin
    Institute of Neuroscience and Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland
    J Neurosci 28:4231-7. 2008
    ..Abeta monomer isolated from human CSF did not affect long-term potentiation. These results strongly support a strategy of passive immunization against soluble Abeta oligomers in early Alzheimer's disease...
  63. ncbi No neurochemical evidence for brain injury caused by heading in soccer
    Henrik Zetterberg
    Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Br J Sports Med 41:574-7. 2007
    ..The possible injurious effect to the brain of heading in soccer is a matter of discussion...
  64. ncbi Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
    Harald Hampel
    School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Trinity Centre for Health Sciences, The Adelaide and Meath Hospital incorporating the National Children s Hospital, Dublin, Ireland
    Alzheimers Dement 4:38-48. 2008
    ..The objective of this article was to review recent progress in selected imaging and neurochemical biomarkers for early diagnosis, classification, progression, and prediction of AD...
  65. ncbi Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
    Henrik Zetterberg
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at Goteborg University, Molndal, Sweden
    Arch Neurol 65:1102-7. 2008
    ....
  66. ncbi Neurochemical aftermath of amateur boxing
    Henrik Zetterberg
    Department of Experimental Neuroscience, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Arch Neurol 63:1277-80. 2006
    ..Little solid information is available on the possible risks for neuronal injury in amateur boxing...
  67. ncbi Re: "The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve"
    Henrik Zetterberg
    Am J Epidemiol 164:707-8; author reply 708. 2006
  68. ncbi Cystatin C in cerebrospinal fluid and multiple sclerosis
    Sara F Hansson
    Department of Clinical Neuroscience, University of Goteborg, Sahlgrenska University Hospital Molndal, Molndal, Sweden
    Ann Neurol 62:193-6; discussion 205. 2007
    ..A recent study using surface-enhanced laser desorption/ionization time-of-flight analysis of cerebrospinal fluid identified a 12.5 kDa truncated isoform of cystatin C (CysC) as a specific biomarker for multiple sclerosis (MS)...
  69. ncbi Transcobalamin polymorphism and serum holo-transcobalamin in relation to Alzheimer's disease
    Andrew McCaddon
    University of Wales College of Medicine, Division of General Practice, Wrexham, UK
    Dement Geriatr Cogn Disord 17:215-21. 2004
    ..008) and between 776C homozygotes and heterozygotes (Cox's F test F(46, 108) = 1.7; p = 0.02). Proportionately fewer TC 776C homozygotes appear to develop AD at any given age, but this will require confirmation in a longitudinal study...